Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADCY5 | O95622 | 11/20 | 0.67 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.46 |
| ▸ | CHKA | P35790 | 4/20 | 0.43 |
| ▸ | FBP1 | P09467 | 1/20 | 0.41 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.41 |
| ▸ | HSPA8 | P11142 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19714857 | 0.90 | ADCY5 (0.65) | ADCY5ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL19715017 | 0.89 | ADCY5 (0.64) | ADCY5ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL19714897 | 0.86 | ADCY5 (0.61) | ADCY5ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL19714928 | 0.85 | ADCY5 (0.48) | ADCY5ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL6045720 | 0.80 | ADCY5 (1.00) | ADCY5ADORA2ACHKA | |
| SCHEMBL14956936 | 0.80 | ADCY5 (1.00) | ADCY5ADORA2ACHKA | |
| SCHEMBL979020 | 0.80 | ADCY5 (1.00) | ADCY5ADORA2ACHKA | |
| SCHEMBL6045679 | 0.80 | ADCY5 (1.00) | ADCY5ADORA2ACHKA | |
| SCHEMBL6045709 | 0.80 | ADCY5 (1.00) | ADCY5ADORA2ACHKA | |
| SCHEMBL6045721 | 0.80 | ADCY5 (1.00) | ADCY5ADORA2ACHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10081633-B2 | Adenylyl cyclase inhibitors, pharmaceutical compositions and method of use thereof | VASADE BIOSCIENCES, INC. | 2018-09-25 | — | — | US | disclosed |
| US-20170362235-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | VASADE BIOSCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170362235-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | VASADE BIOSCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20170362235-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | VASADE BIOSCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10081633-B2 | Adenylyl cyclase inhibitors, pharmaceutical compositions and method of use thereof | ADCY1, ADCY2, ADCY5 | ADCY5 3/4885ADORA3 29/4885ADORA2A 26/4885 |
| US-20170362235-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | ADCY1, ADCY2, ADCY5 | ADCY5 3/4885ADORA3 29/4885ADORA2A 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.